News & Updates

A real-world analysis presented at AAD 2025 shows that patients with alopecia areata (AA) with eyebrow or eyelash hair loss have greater health-related quality of life (HRQoL) burden than those without eyebrow and eyelash involvement.

Two pivotal phase III trials show that a once-daily application of tapinarof cream 1% yields rapid treatment response – as indicated by the vIGA-AD™×BSA* composite score – in individuals with moderate-to-severe atopic dermatitis (AD).

Patients with chronic spontaneous urticaria (CSA) who has uncontrolled disease despite treatment with H1-antihistamines may benefit from using dupilumab, which has been shown to reduce itch and urticaria activity in two phase III trials.